Market Research Report New Study provides Vaginal Atrophy Global Pipeline | Page 3

R&D Progress 32
oxytocin - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
prasterone - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
WC-3011 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects 41
Vaginal Atrophy (Atrophic Vaginitis) - Product Development Milestones 42
Featured News & Press Releases 42
May 03, 2016: Sermonix Pharmaceuticals Announces Dr. Anthony H. Wild as Board Chairman
and Investor 42
Mar 24, 2016: Peptonic Medical receives approval for its clinical Phase 2b study 42
Feb 10, 2016: Sermonix Pharmaceuticals to Give Two Lasofoxifene Presentations at International
Society for the Study of Women's Sexual Health Meeting 43
Jan 05, 2016: DHEA Improves Vaginal Discomfort After Menopause 44
Oct 07, 2015: Sermonix Receives Two Awards at the North American Menopause Society Annual
Meeting 45
Jul 17, 2015: